down arrow

Cytokinetics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US23282W6057
USD
66.54
3.03 (4.77%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Amicus Therapeutics, Inc.
ACADIA Pharmaceuticals, Inc.
Perrigo Co. Plc
Prestige Consumer Healthcare, Inc.
Organon & Co.
Corcept Therapeutics, Inc.
Insmed, Inc.
Cytokinetics, Inc.
Cerevel Therapeutics Holdings, Inc.
MoonLake Immunotherapeutics
Bausch Health Cos., Inc.
Why is Cytokinetics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Net Sales has grown by an annual rate of 35.62% and Operating profit at -224.21% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -6.17
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 34.43%, its profits have fallen by -13.2%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Cytokinetics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Cytokinetics, Inc.
29.18%
0.38
64.71%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
35.62%
EBIT Growth (5y)
-224.21%
EBIT to Interest (avg)
-6.17
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.98
Sales to Capital Employed (avg)
0.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-14.48
EV to EBIT
-6.36
EV to EBITDA
-6.47
EV to Capital Employed
-6.82
EV to Sales
187.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company
NET SALES(HY)

Higher at USD 68.35 MM

RAW MATERIAL COST(Y)

Fallen by -111.02% (YoY

CASH AND EQV(HY)

Highest at USD 1,798.34 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 20.39 times

OPERATING PROFIT(Q)

Highest at USD -109.22 MM

PRE-TAX PROFIT(Q)

Highest at USD -122.77 MM

NET PROFIT(Q)

Highest at USD -122.77 MM

EPS(Q)

Highest at USD -1.12

-2What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -426.93 MM

Here's what is working for Cytokinetics, Inc.
Net Sales
At USD 68.35 MM has Grown at 6,205.17%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (USD MM)

Net Sales
Higher at USD 68.35 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Operating Profit
Highest at USD -109.22 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -122.77 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -122.77 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD -1.12
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv
Highest at USD 1,798.34 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debtors Turnover Ratio
Highest at 20.39 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -111.02% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Cytokinetics, Inc.
Operating Cash Flow
Lowest at USD -426.93 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."